Reflux and Barrett’s disease: revival of endoscopic antireflux procedures?

After the initial enthusiasm at the end of the previous century, interest in endoscopic anti-reflux procedures decreased due to inefficiency or complications with devices, a lack of good clinical trials, or financial problems of the manufacturers. In 2012 some interesting results on new and old devices have been published.

• References

• 1 Arts J, Bisschops R, Blondeau K et al. A double-blind sham-controlled study of the effect of radiofrequency energy on symptoms and distensibility of the gastro-esophageal junction in GERD. Am J Gastroenterol 2012; 107: 222-230
• 2 Arts J, Sifrim D, Rutgeerts P et al. Influence of radiofrequency energy delivery at the gastro-esophageal junction (the Stretta procedure) on symptoms, acid exposure and esophageal sensitivity to acid exposure in gastro-esophageal reflux disease. Dig Dis Sci 2007; 52: 2170-2177
• 3 Bredenoord AJ, Weusten BL, Curvers WL et al. Determinants of perception of heartburn and regurgitation. Gut 2006; 55: 313-318
• 4 Corley DA, Katz P, Wo J et al. temperature controlled radiofrequency energy delivery to the gastroesophageal junction for the treatment of GERD (the Stretta procedure): a randomized, double-blind, sham controlled, multi-center clinical trial. Gastroenterology 2003; 125: 668-676
• 5 Coron E, Sébille V, Cadiot G et al. Radiofrequency energy delivery in PPI-dependent GORD patients: results of a multicentre randomised trial. Aliment Pharmacol Ther 2008; 28: 1147-1158
• 6 Ihde GM, Besancon K, Deljkich E. Short-term safety and symptomatic outcomes of transoral incisionless fundoplication with or without hiatal hernia repair in patients with chronic gastroesophageal reflux disease. Am J Surg 2011; 202: 740-746 ; discussion 746-747
• 7 Cadiere GB, Buset M, Muls V et al. Antireflux transoral incisionless fundoplication using EsophyX: 12-month results of a prospective multicenter study. World J Surg 2008; 32: 1676-1688
• 8 Antoniou SA, Koch OO, Kaindlstorfer A et al. Endoscopic full-thickness plication versus laparoscopic fundoplication: a prospective study on quality of life and symptom control. Surg Endosc 2012; 26: 1063-1068
• 9 Rodríguez L, Rodriguez P, Gómez B et al. Electrical stimulation therapy of the lower esophageal sphincter is successful in treating GERD: final results of open-label prospective trial. Surg Endosc 17.10.2012;
• 10 Chen D, Barber C, McLoughlin P et al. Systematic review of endoscopic treatments for gastro-oesophageal reflux disease. Br J Surg 2009; 96: 128-136
• 11 Laleman W, Van der Merwe S. Covered self-expanding metal stents for transmural drainage of infected pancreatic fluid collections: don’t sell the skin till you have caught the bear or at least spotted the animal. Endoscopy 2012; 44: 1062-1063
• 12 van Vilsteren FG, Pouw RE, Herrero LA et al. Learning to perform endoscopic resection of esophageal neoplasia is associated with significant complications even within a structured training program. Endoscopy 2012; 44: 4-12
• 13 Bisschops R, Wilmer A, Tack J. A survey on gastroenterology training in Europe. Gut 2002; 50: 724-729
• 14 Peters FP, Brakenhoff KP, Curvers WL et al. Endoscopic cap resection for treatment of early Barrett’s neoplasia is safe: a prospective analysis of acute and early complications in 216 procedures. Dis Esophagus 2007; 20: 510-515
• 15 Pech O, Behrens A, May A et al. Long-term results and risk factor analysis for recurrence after curative endoscopic therapy in 349 patients with high-grade intraepithelial neoplasia and mucosal adenocarcinoma in Barrett’s oesophagus. Gut 2008; 57: 1200-1206
• 16 Bisschops R, Bergman J, Wilekens H et al. Endoscopic mucosal resection in the esophagus: how long is the learning curve?. Endoscopy 2011; 43 : A224
• 17 Hur C, Choi SE, Rubenstein JH et al. The cost effectiveness of radiofrequency ablation for Barrett’s esophagus. Gastroenterology 2012; 143: 567-575
• 18 Bennett C, Vakil N, Bergman J et al. Consensus statements for management of Barrett’s dysplasia and early-stage esophageal adenocarcinoma, based on a Delphi process. Gastroenterology 2012; 143: 336-346
• 19 Inadomi JM, Somsouk M, Madanick RD et al. A cost-utility analysis of ablative therapy for Barrett’s esophagus. Gastroenterology 2009; 136: 2101-2114
• 20 Hvid-Jensen F, Pedersen L, Drewes AM et al. Incidence of adenocarcinoma among patients with Barrett’s esophagus. N Engl J Med 2011; 365: 1375-1383
• 21 Shaheen NJ, Overholt BF, Sampliner RE et al. Durability of radiofrequency ablation in Barrett’s esophagus with dysplasia. Gastroenterology 2011; 141: 460-468
• 22 Choi YN, Willekens H, Coremans G et al. Short term side effects after radiofrequency ablation. Are we ready to ablate non-dysplastic Barrett?. Gut 2011; 60 (Suppl. 03) A59
• 23 Titi M, Overhiser A, Ulusarac O et al. Development of subsquamous high-grade dysplasia and adenocarcinoma after successful radiofrequency ablation of Barrett’s esophagus. Gastroenterology 2012; 143: 564-566
• 24 Kastelein F, Spaander MC, Biermann K. Probar-study Group et al. Nonsteroidal anti-inflammatory drugs and statins have chemopreventative effects in patients with Barrett’s esophagus. Gastroenterology 2011; 141: 2000-2008
• 25 Liao LM, Vaughan TL, Corley DA et al. Nonsteroidal anti-inflammatory drug use reduces risk of adenocarcinomas of the esophagus and esophagogastric junction in a pooled analysis. Gastroenterology 2012; 142: 442-452